High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome

Clinical and Experimental Gastroenterology

Volumn 4, Issue 1, 2011, Pages 43-48

  Jolley, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Irritable bowel syndrome; Lactulose breath test; Rifaximin; Small intestinal bacterial overgrowth

Indexed keywords

LACTULOSE; RIFAXIMIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL OVERGROWTH; BLOATING; BREATH ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY;

EID: 79958117849     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S18051     Document Type: Article

References (20)

1. Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: What works and does not work. Gastroenterol Clin North Am. 2005;34(2):319-335.
2. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002;122(6):1701-1704.
3. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20 Suppl 2:1-9.
4. Talley NJ. Irritable bowel syndrome. Intern Med J. 2006;36(11): 724-728.
5. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: Clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139-142.
6. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802-808.
7. Krogius-Kurikka L, Lyra A, Malinen E, et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009;9:95.
8. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(5):512-519.
9. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: Subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51(8): 1297-1301.
10. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412-419.
11. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53(1):169-174.
12. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503-3506.
13. Frissora CL, Cash BD. The role of antibiotics vs conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther. 2007;25(11):1271-1281.
14. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1-S35.
15. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med. 2006;145(8):557-563.
16. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, ElHajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326-333.
17. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with rifaximin. World J Gastroenterol. 2009;15(21): 2628-2631.
18. Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44(8):547-550.
19. Pimentel M, Lembo A, Chey WD, et al. For the TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.
20. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25(7):781-786.